|
US1878751A
(en)
|
1931-03-05 |
1932-09-20 |
Axt Joseph |
Spirit level
|
|
US2192863A
(en)
|
1937-03-12 |
1940-03-05 |
Pennsylvania Res Corp |
Electronic indicator for investigating impulses, vibrations, and the like
|
|
CU22545A1
(es)
|
1994-11-18 |
1999-03-31 |
Centro Inmunologia Molecular |
Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
|
|
GB1458148A
(en)
|
1974-04-19 |
1976-12-08 |
Wyeth John & Brother Ltd |
Carbocyclic-fused ring quinoline derivatives
|
|
JPS57123267A
(en)
|
1981-01-23 |
1982-07-31 |
Kansai Paint Co Ltd |
Thermosetting paint composition
|
|
US4526988A
(en)
|
1983-03-10 |
1985-07-02 |
Eli Lilly And Company |
Difluoro antivirals and intermediate therefor
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
DE3587022T2
(de)
|
1984-02-17 |
1993-06-17 |
Genentech Inc |
Menschlicher transformationswachstumsfaktor und vorlaeufer oder fragment hiervon, zellen, dna, vektoren und verfahren zu ihrer herstellung, zusammensetzungen und produkte, die diese enthalten, sowie davon abgeleitete antikoerper und diagnostizierverfahren.
|
|
US4582789A
(en)
|
1984-03-21 |
1986-04-15 |
Cetus Corporation |
Process for labeling nucleic acids using psoralen derivatives
|
|
DE8411409U1
(de)
|
1984-04-11 |
1984-08-30 |
Dr.-Ing. Walter Frohn-Betriebe, 8000 München |
Entgasungsventil fuer lager- und/oder transportbehaelter
|
|
US4563417A
(en)
|
1984-08-31 |
1986-01-07 |
Miles Laboratories, Inc. |
Nucleic acid hybridization assay employing antibodies to intercalation complexes
|
|
EP0183858B1
(de)
|
1984-11-22 |
1988-09-14 |
Holsten-Brauerei AG |
Bier und Verfahren zu dessen Herstellung
|
|
EP0184365B1
(en)
|
1984-12-04 |
1993-08-04 |
Eli Lilly And Company |
Improvements in the treatment of tumors in mammals
|
|
JPS61148115A
(ja)
|
1984-12-21 |
1986-07-05 |
Tooa Eiyoo Kk |
難溶性薬物の徐放性製剤及びその製造法
|
|
JPS62168137A
(ja)
|
1985-12-20 |
1987-07-24 |
Fuji Photo Film Co Ltd |
ハロゲン化銀カラ−写真感光材料およびその処理方法
|
|
CH656535A5
(en)
|
1986-01-24 |
1986-07-15 |
Spirig Ag |
Process for the production of stable pharmaceutical tablets which disintegrate rapidly in water
|
|
JPH07106295B2
(ja)
|
1986-07-22 |
1995-11-15 |
エーザイ株式会社 |
調湿剤
|
|
US4743450A
(en)
|
1987-02-24 |
1988-05-10 |
Warner-Lambert Company |
Stabilized compositions
|
|
CA1339136C
(en)
|
1987-07-01 |
1997-07-29 |
Sailesh Amilal Varia |
Amorphous form of aztreonam
|
|
US5009894A
(en)
|
1988-03-07 |
1991-04-23 |
Baker Cummins Pharmaceuticals, Inc. |
Arrangement for and method of administering a pharmaceutical preparation
|
|
AU4128089A
(en)
|
1988-09-15 |
1990-03-22 |
Rorer International (Overseas) Inc. |
Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
|
|
US5143854A
(en)
|
1989-06-07 |
1992-09-01 |
Affymax Technologies N.V. |
Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
|
|
US4983615A
(en)
|
1989-06-28 |
1991-01-08 |
Hoechst-Roussel Pharmaceuticals Inc. |
Heteroarylamino- and heteroaryloxypyridinamine compounds which are useful in treating skin disorders
|
|
EP0408496A3
(en)
|
1989-07-12 |
1992-07-01 |
Ciba-Geigy Ag |
Solid dosage form for pharmaceutical substances
|
|
US5120548A
(en)
|
1989-11-07 |
1992-06-09 |
Merck & Co., Inc. |
Swelling modulated polymeric drug delivery device
|
|
US5180818A
(en)
|
1990-03-21 |
1993-01-19 |
The University Of Colorado Foundation, Inc. |
Site specific cleavage of single-stranded dna
|
|
US5210015A
(en)
|
1990-08-06 |
1993-05-11 |
Hoffman-La Roche Inc. |
Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
|
|
EP0834575B1
(en)
|
1990-12-06 |
2001-11-28 |
Affymetrix, Inc. (a Delaware Corporation) |
Identification of nucleic acids in samples
|
|
GB9105677D0
(en)
|
1991-03-19 |
1991-05-01 |
Ici Plc |
Heterocyclic compounds
|
|
US5367057A
(en)
|
1991-04-02 |
1994-11-22 |
The Trustees Of Princeton University |
Tyrosine kinase receptor flk-2 and fragments thereof
|
|
US5721237A
(en)
|
1991-05-10 |
1998-02-24 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
|
|
US5710158A
(en)
|
1991-05-10 |
1998-01-20 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
|
SG64322A1
(en)
|
1991-05-10 |
1999-04-27 |
Rhone Poulenc Rorer Int |
Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
|
|
US5750376A
(en)
|
1991-07-08 |
1998-05-12 |
Neurospheres Holdings Ltd. |
In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
|
|
US5211951A
(en)
|
1991-07-24 |
1993-05-18 |
Merck & Co., Inc. |
Process for the manufacture of bioerodible poly (orthoester)s and polyacetals
|
|
JPH05194259A
(ja)
|
1991-08-30 |
1993-08-03 |
Mitsubishi Kasei Corp |
抗消化性潰瘍剤
|
|
US5200194A
(en)
|
1991-12-18 |
1993-04-06 |
Alza Corporation |
Oral osmotic device
|
|
CA2137275A1
(en)
|
1992-06-03 |
1993-12-09 |
Richard L. Eckert |
Bandage for continuous application of biologicals
|
|
TW271400B
(https=)
|
1992-07-30 |
1996-03-01 |
Pfizer |
|
|
GB9221220D0
(en)
|
1992-10-09 |
1992-11-25 |
Sandoz Ag |
Organic componds
|
|
GB9323290D0
(en)
|
1992-12-10 |
1994-01-05 |
Zeneca Ltd |
Quinazoline derivatives
|
|
JP3254219B2
(ja)
|
1993-01-19 |
2002-02-04 |
ワーナー−ランバート・コンパニー |
安定な経口用のｃｉ−９８１製剤およびその製法
|
|
US6027880A
(en)
|
1995-08-02 |
2000-02-22 |
Affymetrix, Inc. |
Arrays of nucleic acid probes and methods of using the same for detecting cystic fibrosis
|
|
US6156501A
(en)
|
1993-10-26 |
2000-12-05 |
Affymetrix, Inc. |
Arrays of modified nucleic acid probes and methods of use
|
|
JPH07176103A
(ja)
|
1993-12-20 |
1995-07-14 |
Canon Inc |
光磁気記録再生システムならびにこれに用いる磁気ヘッド及び光磁気記録媒体
|
|
GB9326136D0
(en)
|
1993-12-22 |
1994-02-23 |
Erba Carlo Spa |
Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents
|
|
IL112249A
(en)
|
1994-01-25 |
2001-11-25 |
Warner Lambert Co |
Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
|
|
US6811779B2
(en)
|
1994-02-10 |
2004-11-02 |
Imclone Systems Incorporated |
Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
|
|
JP3660391B2
(ja)
|
1994-05-27 |
2005-06-15 |
株式会社東芝 |
半導体装置の製造方法
|
|
JPH0848078A
(ja)
|
1994-08-05 |
1996-02-20 |
Nippon Paper Ind Co Ltd |
感熱記録体
|
|
GB9510757D0
(en)
|
1994-09-19 |
1995-07-19 |
Wellcome Found |
Therapeuticaly active compounds
|
|
US5656454A
(en)
|
1994-10-04 |
1997-08-12 |
President And Fellows Of Harvard College |
Endothelial cell-specific enhancer
|
|
JP3207058B2
(ja)
|
1994-11-07 |
2001-09-10 |
財団法人国際超電導産業技術研究センター |
超電導体薄膜及びその製造方法
|
|
IL115256A0
(en)
|
1994-11-14 |
1995-12-31 |
Warner Lambert Co |
6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
|
|
JPH08176138A
(ja)
|
1994-12-19 |
1996-07-09 |
Mercian Corp |
イソクマリン誘導体
|
|
US5948438A
(en)
|
1995-01-09 |
1999-09-07 |
Edward Mendell Co., Inc. |
Pharmaceutical formulations having improved disintegration and/or absorptivity
|
|
US5658374A
(en)
|
1995-02-28 |
1997-08-19 |
Buckman Laboratories International, Inc. |
Aqueous lecithin-based release aids and methods of using the same
|
|
US5624937A
(en)
|
1995-03-02 |
1997-04-29 |
Eli Lilly And Company |
Chemical compounds as inhibitors of amyloid beta protein production
|
|
US6579314B1
(en)
|
1995-03-10 |
2003-06-17 |
C.R. Bard, Inc. |
Covered stent with encapsulated ends
|
|
DE69536015D1
(de)
|
1995-03-30 |
2009-12-10 |
Pfizer Prod Inc |
Chinazolinone Derivate
|
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
|
US5880141A
(en)
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
|
US5654005A
(en)
|
1995-06-07 |
1997-08-05 |
Andrx Pharmaceuticals, Inc. |
Controlled release formulation having a preformed passageway
|
|
JP3290666B2
(ja)
|
1995-06-07 |
2002-06-10 |
ファイザー・インコーポレーテッド |
複素環式の縮合環ピリミジン誘導体
|
|
JPH0923885A
(ja)
|
1995-07-12 |
1997-01-28 |
Dai Ichi Seiyaku Co Ltd |
遺伝子発現ライブラリー及びその製造法
|
|
GB9514265D0
(en)
|
1995-07-13 |
1995-09-13 |
Wellcome Found |
Hetrocyclic compounds
|
|
GB9520822D0
(en)
|
1995-10-11 |
1995-12-13 |
Wellcome Found |
Therapeutically active compounds
|
|
AR004010A1
(es)
|
1995-10-11 |
1998-09-30 |
Glaxo Group Ltd |
Compuestos heterociclicos
|
|
US6346398B1
(en)
|
1995-10-26 |
2002-02-12 |
Ribozyme Pharmaceuticals, Inc. |
Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
|
|
EP0860433B1
(en)
|
1995-11-07 |
2002-07-03 |
Kirin Beer Kabushiki Kaisha |
Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
|
|
US5849759A
(en)
|
1995-12-08 |
1998-12-15 |
Berlex Laboratories, Inc. |
Naphthyl-substituted benzimidazole derivatives as anti-coagulants
|
|
GB9604361D0
(en)
|
1996-02-29 |
1996-05-01 |
Pharmacia Spa |
4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
|
|
JPH09234074A
(ja)
|
1996-03-04 |
1997-09-09 |
Sumitomo Electric Ind Ltd |
アダプター二本鎖ｄｎａ及びそれを用いたｄｎａ増幅方法
|
|
EP0960104B1
(en)
|
1996-04-17 |
2004-06-16 |
Bristol-Myers Squibb Pharma Company |
N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-one derivatives as factor xa inhibitors
|
|
US6057100A
(en)
|
1996-06-07 |
2000-05-02 |
Eos Biotechnology, Inc. |
Oligonucleotide arrays
|
|
WO1998000134A1
(en)
|
1996-06-28 |
1998-01-08 |
Merck & Co., Inc. |
Fibrinogen receptor antagonists
|
|
AR007857A1
(es)
|
1996-07-13 |
1999-11-24 |
Glaxo Group Ltd |
Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
|
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
|
EA199900021A1
(ru)
|
1996-07-13 |
1999-08-26 |
Глаксо, Груп Лимитед |
Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы
|
|
JPH10147524A
(ja)
|
1996-09-20 |
1998-06-02 |
Nippon Kayaku Co Ltd |
フォルスコリン誘導体含有経口製剤及び医薬製剤の製法
|
|
WO1998013350A1
(en)
|
1996-09-25 |
1998-04-02 |
Zeneca Limited |
Qinoline derivatives inhibiting the effect of growth factors such as vegf
|
|
EP0930305B1
(en)
|
1996-09-30 |
2003-05-14 |
Nihon Nohyaku Co., Ltd. |
1,2,3-thiadiazole derivatives and salts thereof, disease controlling agents for agricultural and horticultural use, and method for the use thereof
|
|
JPH10114655A
(ja)
|
1996-10-09 |
1998-05-06 |
Kyowa Hakko Kogyo Co Ltd |
固形製剤
|
|
EP0837063A1
(en)
|
1996-10-17 |
1998-04-22 |
Pfizer Inc. |
4-Aminoquinazoline derivatives
|
|
WO1998023613A1
(en)
|
1996-11-27 |
1998-06-04 |
Pfizer Inc. |
Fused bicyclic pyrimidine derivatives
|
|
TW486370B
(en)
|
1996-12-25 |
2002-05-11 |
Yamanouchi Pharma Co Ltd |
Rapidly disintegrable pharmaceutical composition
|
|
WO1998032436A1
(en)
|
1997-01-29 |
1998-07-30 |
Eli Lilly And Company |
Treatment for premenstrual dysphoric disorder
|
|
CO4950519A1
(es)
|
1997-02-13 |
2000-09-01 |
Novartis Ag |
Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
|
|
GB2338957B
(en)
|
1997-02-19 |
2001-08-01 |
Berlex Lab |
N-heterocyclic derivatives as nos inhibitors
|
|
US6090556A
(en)
|
1997-04-07 |
2000-07-18 |
Japan Science & Technology Corporation |
Method for quantitatively determining the expression of a gene
|
|
AU7526798A
(en)
|
1997-04-18 |
1998-11-27 |
Smithkline Beecham Plc |
Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders
|
|
JPH10316576A
(ja)
|
1997-05-13 |
1998-12-02 |
Nissui Pharm Co Ltd |
キトサン含有錠剤
|
|
DE69826695T2
(de)
|
1997-05-23 |
2006-02-02 |
Bayer Pharmaceuticals Corp., West Haven |
Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
|
|
US6093742A
(en)
|
1997-06-27 |
2000-07-25 |
Vertex Pharmaceuticals, Inc. |
Inhibitors of p38
|
|
WO1999001738A2
(en)
|
1997-06-30 |
1999-01-14 |
University Of Maryland, Baltimore |
Heparin binding-epidermal growth factor in the diagnosis of interstitial cystitis
|
|
BE1011251A3
(fr)
|
1997-07-03 |
1999-06-01 |
Ucb Sa |
Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine.
|
|
CO4940418A1
(es)
|
1997-07-18 |
2000-07-24 |
Novartis Ag |
Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
|
|
JP3765918B2
(ja)
|
1997-11-10 |
2006-04-12 |
パイオニア株式会社 |
発光ディスプレイ及びその駆動方法
|
|
JP4194678B2
(ja)
|
1997-11-28 |
2008-12-10 |
キリンファーマ株式会社 |
キノリン誘導体およびそれを含む医薬組成物
|
|
ATE529109T1
(de)
|
1997-12-22 |
2011-11-15 |
Bayer Healthcare Llc |
Hemmung der p38 kinase aktivität durch substituierte heterocyclische harnstoffe
|
|
IL136768A0
(en)
|
1997-12-22 |
2001-06-14 |
Bayer Ag |
INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS
|
|
DE69831013T2
(de)
|
1997-12-22 |
2006-04-20 |
Bayer Pharmaceuticals Corp., West Haven |
Inhibierung der raf-kinase durch substituierte heterocyclische harnstoffverbindungen
|
|
CN1213022C
(zh)
|
1997-12-22 |
2005-08-03 |
拜尔有限公司 |
用对称和不对称的取代二苯脲抑制raf激酶
|
|
RS49779B
(sr)
|
1998-01-12 |
2008-06-05 |
Glaxo Group Limited, |
Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
|
|
GB9800575D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
|
SK12752000A3
(sk)
|
1998-02-25 |
2001-03-12 |
Genetics Institute, Inc. |
Inhibítory fosfolipázových enzýmov, farmaceutický prostriedok s ich obsahom a ich použitie
|
|
JP2002505269A
(ja)
|
1998-03-06 |
2002-02-19 |
エウランド インターナショナル ソシエタ ペル アチオニ |
急速崩壊錠剤
|
|
DE19814257A1
(de)
|
1998-03-31 |
1999-10-07 |
Asta Medica Ag |
Brauseformulierungen
|
|
JPH11322596A
(ja)
|
1998-05-12 |
1999-11-24 |
Shionogi & Co Ltd |
白金錯体および環状リン酸エステルアミドを含有する抗癌剤
|
|
UA60365C2
(uk)
|
1998-06-04 |
2003-10-15 |
Пфайзер Продактс Інк. |
Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
|
|
US8097648B2
(en)
|
1998-06-17 |
2012-01-17 |
Eisai R&D Management Co., Ltd. |
Methods and compositions for use in treating cancer
|
|
US6653341B1
(en)
|
1998-06-17 |
2003-11-25 |
Eisai Co., Ltd. |
Methods and compositions for use in treating cancer
|
|
JP4454151B2
(ja)
|
1998-06-17 |
2010-04-21 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
大環状類似体及びそれらの使用並びに調製方法
|
|
EP1121104B1
(en)
|
1998-10-01 |
2005-01-12 |
Novartis AG |
New controlled release oral formulations for rivastigmine
|
|
EA003786B1
(ru)
|
1998-11-19 |
2003-10-30 |
Варнер Ламберт Компани |
N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ
|
|
HK1044159A1
(zh)
|
1998-12-01 |
2002-10-11 |
蛋白质设计实验室股份有限公司 |
抗γ-干扰素的人化抗体
|
|
TWI230618B
(en)
|
1998-12-15 |
2005-04-11 |
Gilead Sciences Inc |
Pharmaceutical compositions of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and tablets or capsules containing the same
|
|
EP1140840B1
(en)
|
1999-01-13 |
2006-03-22 |
Bayer Pharmaceuticals Corp. |
-g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
UA73492C2
(en)
|
1999-01-19 |
2005-08-15 |
|
Aromatic heterocyclic compounds as antiinflammatory agents
|
|
ATE356117T1
(de)
|
1999-01-22 |
2007-03-15 |
Kirin Brewery |
Derivate des n-((chinolinyl)oxy)-phenyl)- harnstoffs und des n-((chinazolinyl)oxy)-phenyl)- harnstoffs mit antitumor aktivität
|
|
UA71945C2
(en)
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
|
JP3270834B2
(ja)
|
1999-01-27 |
2002-04-02 |
ファイザー・プロダクツ・インク |
抗がん剤として有用なヘテロ芳香族二環式誘導体
|
|
PT1154774E
(pt)
|
1999-02-10 |
2005-10-31 |
Astrazeneca Ab |
Derivados de quinazolina como inibidores de angiogenese
|
|
GB9904103D0
(en)
|
1999-02-24 |
1999-04-14 |
Zeneca Ltd |
Quinoline derivatives
|
|
YU13200A
(sh)
|
1999-03-31 |
2002-10-18 |
Pfizer Products Inc. |
Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
|
|
US6342219B1
(en)
|
1999-04-28 |
2002-01-29 |
Board Of Regents, The University Of Texas System |
Antibody compositions for selectively inhibiting VEGF
|
|
AU4778500A
(en)
|
1999-05-20 |
2000-12-12 |
Takeda Chemical Industries Ltd. |
Composition containing ascorbic acid salt
|
|
JP4304357B2
(ja)
|
1999-05-24 |
2009-07-29 |
独立行政法人理化学研究所 |
完全長ｃＤＮＡライブラリーの作成法
|
|
PE20010306A1
(es)
|
1999-07-02 |
2001-03-29 |
Agouron Pharma |
Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
|
|
JP2001047890A
(ja)
|
1999-08-06 |
2001-02-20 |
Toyota Motor Corp |
車両用パワープラントの制御装置
|
|
US6534535B1
(en)
|
1999-08-12 |
2003-03-18 |
Millennium Pharmaceuticals, Inc. |
Inhibitors of factor Xa
|
|
DOP2000000070A
(es)
|
1999-09-28 |
2002-02-28 |
Bayer Healthcare Llc |
Piridinas y piridacinas sustituidas con actividad de inhibición de angiogénesis
|
|
US6762180B1
(en)
|
1999-10-13 |
2004-07-13 |
Boehringer Ingelheim Pharma Kg |
Substituted indolines which inhibit receptor tyrosine kinases
|
|
UA75054C2
(uk)
|
1999-10-13 |
2006-03-15 |
Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг |
Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
|
|
JP2001131071A
(ja)
|
1999-10-29 |
2001-05-15 |
Meiji Seika Kaisha Ltd |
非晶質および非晶質を含有する医薬組成物
|
|
US20080241835A1
(en)
|
1999-11-01 |
2008-10-02 |
Genentech, Inc. |
Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
|
|
CA2389751A1
(en)
|
1999-11-01 |
2001-05-10 |
Curagen Corporation |
Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
|
|
EP1232150B1
(en)
|
1999-11-16 |
2007-10-10 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Urea derivatives as anti-inflammatory agents
|
|
UA75055C2
(uk)
|
1999-11-30 |
2006-03-15 |
Пфайзер Продактс Інк. |
Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
|
|
ATE331514T1
(de)
|
1999-12-22 |
2006-07-15 |
Sugen Inc |
Indolinonderivate zur abänderung der c-kit tyrosinproteinkinase
|
|
AU2223201A
(en)
|
1999-12-24 |
2001-07-09 |
Kirin Beer Kabushiki Kaisha |
Quinoline and quinazoline derivatives and drugs containing the same
|
|
EP1251130B1
(en)
|
1999-12-24 |
2005-02-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Fused purine derivatives
|
|
JP3663382B2
(ja)
|
2000-02-15 |
2005-06-22 |
スージェン・インコーポレーテッド |
ピロール置換２−インドリノン蛋白質キナーゼ阻害剤
|
|
JP3657203B2
(ja)
|
2000-04-21 |
2005-06-08 |
エーザイ株式会社 |
銅クロロフィリン塩含有液剤組成物
|
|
CN1116047C
(zh)
|
2000-06-05 |
2003-07-30 |
华中科技大学 |
用泥鳅制成的护肝功能食品及其制备方法
|
|
EP1287029A2
(en)
|
2000-06-09 |
2003-03-05 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of colon cancer
|
|
AU2001277621A1
(en)
|
2000-08-09 |
2002-03-04 |
Astrazeneca Ab |
Antiangiogenic bicyclic derivatives
|
|
AU9598601A
(en)
|
2000-10-20 |
2002-04-29 |
Eisai Co Ltd |
Nitrogenous aromatic ring compounds
|
|
TWI283575B
(en)
|
2000-10-31 |
2007-07-11 |
Eisai Co Ltd |
Medicinal compositions for concomitant use as anticancer agent
|
|
ATE369894T1
(de)
|
2000-11-22 |
2007-09-15 |
Novartis Pharma Gmbh |
Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität
|
|
JP2004517080A
(ja)
|
2000-11-29 |
2004-06-10 |
グラクソ グループ リミテッド |
Ｔｉｅ−２および／またはｖｅｇｆｒ−２の阻害剤として有用なベンゾイミダゾール誘導体
|
|
US6544552B2
(en)
|
2001-01-11 |
2003-04-08 |
Particle And Coating Technologies, Inc. |
Method of producing porous tablets with improved dissolution properties
|
|
CA2439402A1
(en)
|
2001-03-02 |
2002-09-12 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Pcr method
|
|
WO2002072578A2
(en)
|
2001-03-08 |
2002-09-19 |
Millennium Pharmaceuticals |
(homo) piperazine substituted quinolines for inhibiting the phosphorylation of kinases
|
|
EA010184B1
(ru)
|
2001-04-06 |
2008-06-30 |
Уайт |
Применение противоопухолевых комбинаций рапамицина с гемцитабином или 5-фторурацилом
|
|
EP1379545A2
(de)
|
2001-04-19 |
2004-01-14 |
Gesellschaft für biotechnologische Forschung mbH (GBF) |
Verfahren zur herstellung stabiler, regenerierbarer antikörper-arrays
|
|
DK1382604T3
(da)
|
2001-04-27 |
2006-04-18 |
Kirin Brewery |
Quinolinderivater med en azolylgruppe og quinazolinderivater
|
|
JP3602513B2
(ja)
|
2001-04-27 |
2004-12-15 |
麒麟麦酒株式会社 |
アゾリル基を有するキノリン誘導体およびキナゾリン誘導体
|
|
JP2003026576A
(ja)
|
2001-05-09 |
2003-01-29 |
Eisai Co Ltd |
味覚改善製剤
|
|
US6812341B1
(en)
|
2001-05-11 |
2004-11-02 |
Ambion, Inc. |
High efficiency mRNA isolation methods and compositions
|
|
CA2444867C
(en)
|
2001-05-16 |
2010-08-17 |
Novartis Ag |
Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
|
|
US6599902B2
(en)
|
2001-05-30 |
2003-07-29 |
Sugen, Inc. |
5-aralkysufonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
|
|
AU2002313249B2
(en)
|
2001-06-22 |
2008-08-21 |
Kirin Pharma Kabushiki Kaisha |
Quinoline derivative and quinazoline derivate inhibiting self-phosphorylation of hepatocytus proliferator receptor, and medicinal composition containing the same
|
|
GB0117144D0
(en)
|
2001-07-13 |
2001-09-05 |
Glaxo Group Ltd |
Process
|
|
US20030013208A1
(en)
|
2001-07-13 |
2003-01-16 |
Milagen, Inc. |
Information enhanced antibody arrays
|
|
JP4827154B2
(ja)
|
2001-07-25 |
2011-11-30 |
株式会社オーイズミ |
遊技装置
|
|
GB0119467D0
(en)
|
2001-08-09 |
2001-10-03 |
Smithkline Beecham Plc |
Novel compound
|
|
AU2002341621A1
(en)
|
2001-09-10 |
2003-03-24 |
Meso Scale Technologies, Llc |
Methods, reagents, kits and apparatus for protein function analysis
|
|
EP1427379B1
(en)
|
2001-09-20 |
2008-08-13 |
AB Science |
Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
|
|
AU2002341881B2
(en)
|
2001-09-27 |
2008-05-08 |
Allergan, Inc. |
3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
|
|
US20040266779A1
(en)
|
2001-09-27 |
2004-12-30 |
Anderson Kenneth C. |
Use of c-kit inhibitors for the treatment of myeloma
|
|
AU2002340139A1
(en)
|
2001-10-09 |
2003-04-22 |
The University Of Cincinnati |
Inhibitors of the egf receptor for the treatment of thyroid cancer
|
|
US7521053B2
(en)
|
2001-10-11 |
2009-04-21 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
|
US7658924B2
(en)
|
2001-10-11 |
2010-02-09 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
|
EP1447405A4
(en)
|
2001-10-17 |
2005-01-12 |
Kirin Brewery |
CHINOLIN OR CHINAZOLINE DERIVATIVES THAT PREVENT THE AUTOPHOSPHORYLATION OF RECEPTORS FOR THE FIBROBLAST GROWTH FACTOR
|
|
AR037438A1
(es)
|
2001-11-27 |
2004-11-10 |
Wyeth Corp |
3-cianoquinolinas como inhibidores de egf-r y her2 quinasas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de medicamentos
|
|
GB0201508D0
(en)
|
2002-01-23 |
2002-03-13 |
Novartis Ag |
Organic compounds
|
|
JP2003252737A
(ja)
|
2002-03-04 |
2003-09-10 |
Shin Etsu Chem Co Ltd |
口腔用組成物
|
|
EP2298346A3
(en)
|
2002-03-04 |
2011-11-16 |
Imclone LLC |
Human antibodies specific to kdr and uses thereof
|
|
JP4542783B2
(ja)
|
2002-03-05 |
2010-09-15 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
スルホンアミド含有複素環化合物及び血管新生抑制剤とを組み合わせてなる抗腫瘍剤
|
|
WO2003077842A2
(en)
|
2002-03-12 |
2003-09-25 |
Bristol-Myers Squibb Company |
Palatable oral suspension and method
|
|
WO2003079020A2
(en)
|
2002-03-20 |
2003-09-25 |
Dana-Farber Cancer Institute Inc. |
Methods and compositions for the identification, assessment, and therapy of small cell lung cancer
|
|
US6790852B2
(en)
|
2002-04-18 |
2004-09-14 |
Hoffmann-La Roche Inc. |
2-(2,6-dichlorophenyl)-diarylimidazoles
|
|
JPWO2003093238A1
(ja)
|
2002-05-01 |
2005-09-08 |
麒麟麦酒株式会社 |
マクロファージコロニー刺激因子受容体自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体
|
|
PE20040522A1
(es)
|
2002-05-29 |
2004-09-28 |
Novartis Ag |
Derivados de diarilurea dependientes de la cinasa de proteina
|
|
UA77303C2
(en)
|
2002-06-14 |
2006-11-15 |
Pfizer |
Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
|
|
AU2003281200A1
(en)
|
2002-07-03 |
2004-01-23 |
Tasuku Honjo |
Immunopotentiating compositions
|
|
WO2004006862A2
(en)
|
2002-07-16 |
2004-01-22 |
Children's Medical Center Corporation |
A method for the modulation of angiogenesis
|
|
EP3656802A1
(en)
|
2002-07-22 |
2020-05-27 |
Aspen Aerogels Inc. |
Polyimide aerogels, carbon aerogels, and metal carbide aerogels and methods of making same
|
|
US7169936B2
(en)
|
2002-07-23 |
2007-01-30 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
|
|
US7252976B2
(en)
|
2002-08-28 |
2007-08-07 |
Board Of Regents The University Of Texas System |
Quantitative RT-PCR to AC133 to diagnose cancer and monitor angiogenic activity in a cell sample
|
|
US20060004029A1
(en)
|
2002-08-30 |
2006-01-05 |
Akihiko Tsuruoka |
Nitrogen-containing aromatic derivatives
|
|
WO2004032872A2
(en)
|
2002-10-09 |
2004-04-22 |
Kosan Biosciences, Inc. |
Epo D + 5-FU/GEMCITABINE
|
|
GB0223380D0
(en)
|
2002-10-09 |
2002-11-13 |
Astrazeneca Ab |
Combination therapy
|
|
WO2004035052A1
(ja)
|
2002-10-16 |
2004-04-29 |
Takeda Pharmaceutical Company Limited |
安定な固形製剤
|
|
JP4749660B2
(ja)
|
2002-10-16 |
2011-08-17 |
武田薬品工業株式会社 |
安定な固形製剤
|
|
MXPA05003660A
(es)
|
2002-10-21 |
2005-06-08 |
Warner Lambert Co |
Derivados de quinolina como antagonistas de crth2.
|
|
EP1566379A4
(en)
|
2002-10-29 |
2005-11-09 |
Kirin Brewery |
CHINOLINE DERIVATIVES AND CHINAZOLINE DERIVATIVES AS INHIBITORS OF FLT3 AUTOPHOSPHORYLATION AND THE MEDICAL COMPOSITIONS CONTAINING THEREOF
|
|
DE10250711A1
(de)
|
2002-10-31 |
2004-05-19 |
Degussa Ag |
Pharmazeutische und kosmetische Zubereitungen
|
|
JP2006508184A
(ja)
|
2002-11-06 |
2006-03-09 |
サイクラセル・リミテッド |
Ｃｄｋ阻害剤及びゲムシタビンを含む医薬組成物
|
|
GB0226434D0
(en)
|
2002-11-13 |
2002-12-18 |
Astrazeneca Ab |
Combination product
|
|
ITSV20020056A1
(it)
|
2002-11-14 |
2004-05-15 |
Alstom Transp Spa |
Dispositivo e metodo di verifica di motori software logici di comando di impianti ferroviari, in particolare di impianti di stazione
|
|
AR042042A1
(es)
|
2002-11-15 |
2005-06-08 |
Sugen Inc |
Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
|
|
CN101899114A
(zh)
|
2002-12-23 |
2010-12-01 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
ATE552236T1
(de)
|
2003-01-14 |
2012-04-15 |
Cytokinetics Inc |
Verbindungen, zusammensetzungen und verfahren zur behandlung von herzinsuffizienz
|
|
US7563869B2
(en)
|
2003-01-23 |
2009-07-21 |
Ono Pharmaceutical Co., Ltd. |
Substance specific to human PD-1
|
|
JP3581361B1
(ja)
|
2003-02-17 |
2004-10-27 |
株式会社脳機能研究所 |
脳活動測定装置
|
|
EP1594470A4
(en)
|
2003-02-19 |
2007-10-17 |
Biovail Lab Int Srl |
QUICK ABSORPTION 5-HT SELECTIVE AGONIST FORMULATIONS
|
|
DK1603570T5
(da)
|
2003-02-26 |
2013-12-09 |
Sugen Inc |
Aminoheteroarylforbindelser som proteinkinaseinhibitorer
|
|
JP2006519874A
(ja)
|
2003-03-05 |
2006-08-31 |
セルジーン・コーポレーション |
ジフェニルエチレン化合物およびその使用
|
|
ATE508747T1
(de)
|
2003-03-10 |
2011-05-15 |
Eisai R&D Man Co Ltd |
C-kit kinase-hemmer
|
|
RU2366655C2
(ru)
|
2003-03-14 |
2009-09-10 |
Оно Фармасьютикал Ко., Лтд. |
Азотсодержащие гетероциклические производные и лекарственные средства, содержащие их в качестве активного ингредиента
|
|
RU2312109C2
(ru)
|
2003-03-14 |
2007-12-10 |
Тайсо Фармасьютикал Ко., Лтд. |
Моноклональное антитело и продуцирующая его гибридома
|
|
AU2003214486A1
(en)
|
2003-04-02 |
2004-10-25 |
Pliva-Istrazivanje I Razvoj D.O.O. |
Pharmaceutical compositions having reduced bitter taste
|
|
US20050014753A1
(en)
|
2003-04-04 |
2005-01-20 |
Irm Llc |
Novel compounds and compositions as protein kinase inhibitors
|
|
US20070117842A1
(en)
|
2003-04-22 |
2007-05-24 |
Itaru Arimoto |
Polymorph of 4-[3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6- quinolinecarboxamide and a process for the preparation of the same
|
|
EP1473043A1
(en)
|
2003-04-29 |
2004-11-03 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Pharmaceutical combination for the treatment of diseases involving cell proliferation, migration or apotosis of myeloma cells, or angiogenesis
|
|
US7107104B2
(en)
|
2003-05-30 |
2006-09-12 |
Medtronic, Inc. |
Implantable cortical neural lead and method
|
|
JP2005008534A
(ja)
|
2003-06-17 |
2005-01-13 |
Soc De Conseils De Recherches & D'applications Scientifiques (Scras) |
抗癌剤及び癌の治療方法
|
|
EP1648465B1
(en)
|
2003-07-10 |
2010-08-25 |
AstraZeneca AB |
Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
|
|
ATE395052T1
(de)
|
2003-08-15 |
2008-05-15 |
Ab Science |
Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes
|
|
JP4769720B2
(ja)
|
2003-08-21 |
2011-09-07 |
オーエスアイ・ファーマシューテイカルズ・エル・エル・シー |
Ｎ−置換ベンズイミダゾリルｃ−Ｋｉｔ阻害剤
|
|
AU2004268948A1
(en)
|
2003-08-21 |
2005-03-10 |
Osi Pharmaceuticals, Inc. |
N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
|
|
US7485658B2
(en)
|
2003-08-21 |
2009-02-03 |
Osi Pharmaceuticals, Inc. |
N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors
|
|
US7312243B1
(en)
*
|
2003-08-29 |
2007-12-25 |
Jay Pravda |
Materials and methods for treatment of gastrointestinal disorders
|
|
US20080085902A1
(en)
|
2003-09-23 |
2008-04-10 |
Guido Bold |
Combination Of A Vegf Receptor Inhibitor Or With A Chemotherapeutic Agent
|
|
EP2210607B1
(en)
|
2003-09-26 |
2011-08-17 |
Exelixis Inc. |
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
|
|
KR200340552Y1
(ko)
|
2003-10-08 |
2004-02-11 |
주식회사 엘지화학 |
창틀 내부에 블라인드 및 방범창 설치가 용이한 이중창틀
|
|
JP2005124034A
(ja)
|
2003-10-20 |
2005-05-12 |
Nippon Telegr & Teleph Corp <Ntt> |
発信者の特定及び発信者への呼び返しを可能とする回線設定方法
|
|
US7683172B2
(en)
|
2003-11-11 |
2010-03-23 |
Eisai R&D Management Co., Ltd. |
Urea derivative and process for preparing the same
|
|
PE20051046A1
(es)
|
2003-11-28 |
2006-01-11 |
Novartis Ag |
Derivados de diaril-urea en el tratamiento de enfermedades dependientes de la quinasa de proteina
|
|
EP1711196A4
(en)
|
2003-12-05 |
2011-09-14 |
Bristol Myers Squibb Co |
INHIBITORS OF TYPE-2 VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS
|
|
KR100804566B1
(ko)
|
2003-12-25 |
2008-02-20 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
4-(3-클로로-4-(시클로프로필아미노카르보닐)아미노페녹시)-7-메톡시-6-퀴놀린카르복사미드의 염 또는 그 용매화물의 결정 및 이들의 제조 방법
|
|
AU2006269927B2
(en)
|
2004-01-12 |
2013-05-16 |
The Trustees Of The University Of Pennsylvania |
Drug-containing implants and methods of use thereof
|
|
GEP20084439B
(en)
|
2004-01-23 |
2008-07-25 |
Amgen Inc |
Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof
|
|
US7531532B2
(en)
|
2004-02-27 |
2009-05-12 |
Eisai R&D Management Co., Ltd. |
Pyridine derivative and pyrimidine derivative
|
|
KR20050091462A
(ko)
|
2004-03-12 |
2005-09-15 |
한국과학기술연구원 |
푸로피리미딘 화합물 및 이를 포함하는 ｄｄｒ2 티로신키나아제 활성 저해제
|
|
JP4341454B2
(ja)
|
2004-04-08 |
2009-10-07 |
トヨタ自動車株式会社 |
固体電解質型燃料電池の製造方法
|
|
US7459562B2
(en)
|
2004-04-23 |
2008-12-02 |
Bristol-Myers Squibb Company |
Monocyclic heterocycles as kinase inhibitors
|
|
ES2311992T3
(es)
|
2004-05-21 |
2009-02-16 |
Novartis Vaccines And Diagnostics, Inc. |
Derivados de quinolina sustituida com,o inhibidores de cinesina mitotica.
|
|
NZ551406A
(en)
|
2004-06-03 |
2010-03-26 |
Hoffmann La Roche |
Treatment of non small cell lung cancer with gemcitabine and erlotinib (an egfr kinase inhibitor)
|
|
SI2522663T1
(sl)
|
2004-06-03 |
2015-08-31 |
Eisai R&D Management Co., Ltd. |
Vmesne spojine za pripravo halihondrina B
|
|
US20080214606A1
(en)
|
2004-06-18 |
2008-09-04 |
The Government of the United States of America as represented by The Secretary of the Dept. of ..... |
Methods for the Identification and Use of Compounds Suitable for the Treatment of Drug Resistant Cancer Cells
|
|
US7173031B2
(en)
|
2004-06-28 |
2007-02-06 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
|
US20050288521A1
(en)
|
2004-06-29 |
2005-12-29 |
Phytogen Life Sciences Inc. |
Semi-synthetic conversion of paclitaxel to docetaxel
|
|
US7977345B2
(en)
|
2004-07-02 |
2011-07-12 |
Exelixis, Inc. |
c-MET modulators and method of use
|
|
US8772269B2
(en)
|
2004-09-13 |
2014-07-08 |
Eisai R&D Management Co., Ltd. |
Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
|
|
WO2006030947A1
(ja)
|
2004-09-13 |
2006-03-23 |
Eisai R & D Management Co., Ltd. |
スルホンアミド含有化合物の血管新生阻害物質との併用
|
|
ATE428421T1
(de)
|
2004-09-17 |
2009-05-15 |
Eisai R&D Man Co Ltd |
Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
|
|
JP2008514635A
(ja)
|
2004-09-27 |
2008-05-08 |
コーザン バイオサイエンシス インコーポレイテッド |
特異的キナーゼ阻害剤
|
|
WO2006038552A1
(ja)
|
2004-10-01 |
2006-04-13 |
Eisai R & D Management Co., Ltd. |
微粒子含有組成物およびその製造方法
|
|
BRPI0518209A
(pt)
|
2004-10-19 |
2008-11-04 |
Amgen Inc |
agentes de ligação especìficos à angiopoietina-2
|
|
AU2005336924A1
(en)
|
2004-11-22 |
2007-04-12 |
King Pharmaceuticals Research & Development, Inc. |
Enhancing treatment of cancer and HIF-1 mediated disoders with adenosine A3 receptor antagonists
|
|
RU2361867C2
(ru)
|
2004-11-23 |
2009-07-20 |
Донг Вха Фармасьютикал. Инд. Ко., Лтд. |
Диметансульфонат n-гидрокси-4{5-[4-(5-изопропил-2-метил-1, 3-тиазол-4-ил)фенокси]пентокси}бензамидина
|
|
JP2008521900A
(ja)
|
2004-11-30 |
2008-06-26 |
アムジエン・インコーポレーテツド |
キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用
|
|
CN100341504C
(zh)
|
2004-12-01 |
2007-10-10 |
鲁南制药集团股份有限公司 |
佐米曲普坦速释制剂
|
|
US7612200B2
(en)
|
2004-12-07 |
2009-11-03 |
Locus Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
|
ZA200705695B
(en)
|
2004-12-21 |
2009-02-25 |
Astrazeneca Ab |
Antibodies directed to angiopoietin-2 and uses thereof
|
|
JP2006230816A
(ja)
|
2005-02-25 |
2006-09-07 |
H & A Investment:Kk |
サンダル用ホルダー
|
|
SI1859793T1
(sl)
|
2005-02-28 |
2011-08-31 |
Eisai R&D Man Co Ltd |
Nova kombinirana uporaba sulfonamidne spojine za zdravljenje raka
|
|
JP5106098B2
(ja)
|
2005-02-28 |
2012-12-26 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
スルホンアミド化合物の抗癌剤との新規併用
|
|
US20080286282A1
(en)
|
2005-02-28 |
2008-11-20 |
Eisai R & D Management Co., Ltd. |
Novel Use of Sulfonamide Compound in Combination with Angiogenesis Inhibitor
|
|
DK2439273T3
(da)
|
2005-05-09 |
2019-06-03 |
Ono Pharmaceutical Co |
Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
|
|
US7846941B2
(en)
|
2005-05-17 |
2010-12-07 |
Plexxikon, Inc. |
Compounds modulating c-kit and c-fms activity and uses therefor
|
|
UA95244C2
(ru)
|
2005-06-22 |
2011-07-25 |
Плексикон, Инк. |
Соединения и способ модулирования активности киназ, и показания для их применения
|
|
US7550483B2
(en)
|
2005-06-23 |
2009-06-23 |
Eisai R&D Management Co., Ltd. |
Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for preparing the same
|
|
CN101233111A
(zh)
|
2005-06-23 |
2008-07-30 |
卫材R&D管理有限公司 |
4-（3-氯-4-（环丙基氨基羰基）氨基苯氧基）-7-甲氧基-6-喹啉羧酸酰胺的无定形盐及其制备方法
|
|
US20090305994A1
(en)
|
2005-06-29 |
2009-12-10 |
D Andrea Lucas Domenico |
Compounds Modulating Vegf Receptor and Uses Thereof
|
|
PT1907424E
(pt)
|
2005-07-01 |
2015-10-09 |
Squibb & Sons Llc |
Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
|
|
EP1901719A2
(en)
|
2005-07-11 |
2008-03-26 |
Nycomed Danmark ApS |
Benzimidazole formulation
|
|
US8101799B2
(en)
|
2005-07-21 |
2012-01-24 |
Ardea Biosciences |
Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
|
|
US20080219977A1
(en)
|
2005-07-27 |
2008-09-11 |
Isaiah Josh Fidler |
Combinations Comprising Gemcitabine and Tyrosine Kinase Inhibitors for the Treatment of Pancreatic Cancer
|
|
WO2007015569A1
(ja)
|
2005-08-01 |
2007-02-08 |
Eisai R & D Management Co., Ltd. |
血管新生阻害物質の効果を予測する方法
|
|
JP4989476B2
(ja)
|
2005-08-02 |
2012-08-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
血管新生阻害物質の効果を検定する方法
|
|
CN101198590B
(zh)
|
2005-08-24 |
2012-05-09 |
卫材R&D管理有限公司 |
吡啶衍生物及嘧啶衍生物（3）
|
|
CA2620594C
(en)
|
2005-09-01 |
2012-08-21 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition having improved disintegratability
|
|
CN1308012C
(zh)
|
2005-11-02 |
2007-04-04 |
广州中医药大学第二附属医院 |
一种治疗脑出血的中药组合物及其制备方法
|
|
AU2006309551B2
(en)
|
2005-11-07 |
2012-04-19 |
Eisai R & D Management Co., Ltd. |
Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
|
|
EP1964837A4
(en)
|
2005-11-22 |
2010-12-22 |
Eisai R&D Man Co Ltd |
Antitumor agent against multiple myeloma
|
|
PL1959955T3
(pl)
|
2005-12-05 |
2011-04-29 |
Pfizer Prod Inc |
Sposób traktowania nieprawidłowego wzrostu komórek
|
|
AR059066A1
(es)
|
2006-01-27 |
2008-03-12 |
Amgen Inc |
Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
|
|
KR100728926B1
(ko)
|
2006-03-20 |
2007-06-15 |
삼성전자주식회사 |
3축 힌지 구조를 갖는 휴대용 전자기기
|
|
CN104706637A
(zh)
|
2006-05-18 |
2015-06-17 |
卫材R&D管理有限公司 |
针对甲状腺癌的抗肿瘤剂
|
|
US7321241B1
(en)
|
2006-06-15 |
2008-01-22 |
California Micro Devices |
Bidirectional buffer with slew rate control and method of bidirectionally transmitting signals with slew rate control
|
|
CA2661333C
(en)
|
2006-08-23 |
2014-08-05 |
Eisai R&D Management Co., Ltd. |
Salt of phenoxypyridine derivative or crystal thereof and process for producing the same
|
|
WO2008026748A1
(en)
|
2006-08-28 |
2008-03-06 |
Eisai R & D Management Co., Ltd. |
Antitumor agent for undifferentiated gastric cancer
|
|
US7790885B2
(en)
|
2006-08-31 |
2010-09-07 |
Eisai R&D Management Co., Ltd. |
Process for preparing phenoxypyridine derivatives
|
|
AU2007293280A1
(en)
|
2006-09-07 |
2008-03-13 |
Astrazeneca Ab |
Method for evaluating patients for treatment with drugs targeting RET receptor tyrosine kinase
|
|
JP2009184925A
(ja)
|
2006-11-02 |
2009-08-20 |
Dai Ichi Seiyaku Co Ltd |
５−（１ｈ−１，２，３−トリアゾール−４−イル）−１ｈ−ピラゾール誘導体
|
|
JPWO2008088088A1
(ja)
|
2007-01-19 |
2010-05-13 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
膵癌治療用組成物
|
|
KR20090111847A
(ko)
|
2007-01-19 |
2009-10-27 |
아디아 바이오사이언스즈 인크. |
Ｍｅｋ 억제제
|
|
CA2676796C
(en)
|
2007-01-29 |
2016-02-23 |
Eisai R & D Management Co., Ltd. |
Composition for treatment of undifferentiated gastric cancer
|
|
AU2008217931A1
(en)
|
2007-02-23 |
2008-08-28 |
Eisai R & D Management Co., Ltd. |
Pyridine or pyrimidine derivative having excellent cell growth inhibition effect and excellent anti-tumor effect on cell strain having amplification of HGFR gene
|
|
JPWO2008108386A1
(ja)
|
2007-03-05 |
2010-06-17 |
協和発酵キリン株式会社 |
医薬組成物
|
|
EP2133095A4
(en)
|
2007-03-05 |
2012-09-26 |
Kyowa Hakko Kirin Co Ltd |
PHARMACEUTICAL COMPOSITION
|
|
GB2448181B
(en)
|
2007-04-05 |
2011-11-09 |
Ford Global Tech Llc |
Vehicle headlight beam controls
|
|
US7901888B2
(en)
|
2007-05-09 |
2011-03-08 |
The Regents Of The University Of California |
Multigene diagnostic assay for malignant thyroid neoplasm
|
|
US7807172B2
(en)
|
2007-06-13 |
2010-10-05 |
University Of Washington |
Methods and compositions for detecting thyroglobulin in a biological sample
|
|
BR122017025062B8
(pt)
|
2007-06-18 |
2021-07-27 |
Merck Sharp & Dohme |
anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
|
|
PE20090368A1
(es)
|
2007-06-19 |
2009-04-28 |
Boehringer Ingelheim Int |
Anticuerpos anti-igf
|
|
CA2924436A1
(en)
|
2007-07-30 |
2009-02-05 |
Ardea Biosciences, Inc. |
Pharmaceutical combinations of n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide as inhibitors of mek and methods of use
|
|
BRPI0817909B1
(pt)
|
2007-10-03 |
2022-06-21 |
Eisai R&D Management Co., Ltd |
Métodos de obtenção e de preparação de uma composição diastereomericamente pura, compostos, e método para produzir os referidos compostos
|
|
US8952035B2
(en)
*
|
2007-11-09 |
2015-02-10 |
Eisai R&D Management Co., Ltd. |
Combination of anti-angiogenic substance and anti-tumor platinum complex
|
|
JP2009132660A
(ja)
|
2007-11-30 |
2009-06-18 |
Eisai R & D Management Co Ltd |
食道癌治療用組成物
|
|
KR101506062B1
(ko)
|
2008-01-29 |
2015-03-25 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
혈관 저해 물질과 탁산의 병용
|
|
GB2456907A
(en)
|
2008-01-30 |
2009-08-05 |
Astrazeneca Ab |
Method for determining subsequent VEGFR2 inhibitor therapy comprising measuring baseline VEGF level.
|
|
WO2009111648A1
(en)
|
2008-03-05 |
2009-09-11 |
Vicus Therapeutics, Llc |
Compositions and methods for mucositis and oncology therapies
|
|
US8044240B2
(en)
|
2008-03-06 |
2011-10-25 |
Ardea Biosciences Inc. |
Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof
|
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
|
MX2010011314A
(es)
|
2008-04-14 |
2010-11-12 |
Ardea Biosciences Inc |
Composiciones y metodos de preparacion y uso de las mismas.
|
|
WO2009137649A2
(en)
|
2008-05-07 |
2009-11-12 |
The Trustees Of The University Of Pennsylvania |
Methods for treating thyroid cancer
|
|
AU2009246263B2
(en)
|
2008-05-14 |
2014-08-21 |
Amgen Inc. |
Combinations VEGF(R) inhibitors and hepatocyte growth factor (c-Met) inhibitors for the treatment of cancer
|
|
WO2009150255A2
(en)
|
2008-06-13 |
2009-12-17 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Markers for predicting response and survival in anti-egfr treated patients
|
|
US20110105521A1
(en)
|
2008-07-11 |
2011-05-05 |
Novartis Ag |
Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of ras/raf/mek pathway
|
|
JP2012500855A
(ja)
|
2008-08-25 |
2012-01-12 |
アンプリミューン、インコーポレーテッド |
Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
|
|
US8552154B2
(en)
|
2008-09-26 |
2013-10-08 |
Emory University |
Anti-PD-L1 antibodies and uses therefor
|
|
JP5439494B2
(ja)
|
2008-10-21 |
2014-03-12 |
バイエル ヘルスケア エルエルシー |
肝細胞癌と関連するシグネチャ遺伝子の同定
|
|
EP3255060A1
(en)
|
2008-12-09 |
2017-12-13 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
WO2010086964A1
(ja)
|
2009-01-28 |
2010-08-05 |
株式会社 静岡カフェイン工業所 |
がん治療のための併用療法
|
|
EP2461835A4
(en)
|
2009-08-07 |
2013-05-15 |
Wistar Inst |
COMPOSITIONS WITH JARID1B INHIBITORS AND METHOD FOR THE TREATMENT OF CANCER
|
|
MY162940A
(en)
|
2009-08-19 |
2017-07-31 |
Eisai R&D Man Co Ltd |
Quinoline derivative-containing pharmaceutical composition
|
|
WO2011022335A1
(en)
|
2009-08-21 |
2011-02-24 |
Mount Sinai School Of Medicine Of New York University |
Methods of using cd44 fusion proteins to treat cancer
|
|
EP2293071A1
(en)
|
2009-09-07 |
2011-03-09 |
Universität Zu Köln |
Biomarker for colorectal cancer
|
|
WO2011066342A2
(en)
|
2009-11-24 |
2011-06-03 |
Amplimmune, Inc. |
Simultaneous inhibition of pd-l1/pd-l2
|
|
RU2579511C2
(ru)
|
2010-01-26 |
2016-04-10 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Производные фуро[3,2-в]пирана, применимые в синтезе аналогов
|
|
CN102958523B
(zh)
|
2010-06-25 |
2014-11-19 |
卫材R&D管理有限公司 |
使用具有激酶抑制作用的组合的抗肿瘤剂
|
|
US20130225581A1
(en)
|
2010-07-16 |
2013-08-29 |
Kyowa Hakko Kirin Co., Ltd |
Nitrogen-containing aromatic heterocyclic derivative
|
|
WO2012010552A1
(en)
|
2010-07-19 |
2012-01-26 |
F. Hoffmann-La Roche Ag |
Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
|
|
KR20130126576A
(ko)
|
2010-07-19 |
2013-11-20 |
에프. 호프만-라 로슈 아게 |
항암요법에 반응할 가능성이 증가된 환자를 확인하는 방법
|
|
CA2805618A1
(en)
|
2010-07-19 |
2012-01-26 |
F. Hoffmann-La Roche Ag |
Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
|
|
SG187012A1
(en)
|
2010-07-19 |
2013-02-28 |
Hoffmann La Roche |
Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer
|
|
WO2012019300A1
(en)
|
2010-08-10 |
2012-02-16 |
Siu K W Michael |
Endometrial cancer biomarkers and methods of identifying and using same
|
|
US20120077837A1
(en)
*
|
2010-09-24 |
2012-03-29 |
Eisai R&D Management Co., Ltd. |
Anti-tumor agent
|
|
US20120184452A1
(en)
|
2011-01-13 |
2012-07-19 |
Universidade De Santiago De Compostela |
Methods for diagnosing follicular thyroid cancer
|
|
RU2568258C2
(ru)
|
2011-02-28 |
2015-11-20 |
Саншайн Лейк Фарма Ко., Лтд |
Замещенные соединения хинолина и способы их использования
|
|
CA2864394C
(en)
|
2011-03-02 |
2021-10-19 |
Jack Roth |
A method of predicting a response to a tusc2 therapy
|
|
CA2828940C
(en)
|
2011-03-10 |
2024-04-16 |
Provectus Pharmaceuticals, Inc. |
Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
|
|
PT2691112T
(pt)
|
2011-03-31 |
2018-07-10 |
Merck Sharp & Dohme |
Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados
|
|
CN103402519B
(zh)
|
2011-04-18 |
2015-11-25 |
卫材R&D管理有限公司 |
肿瘤治疗剂
|
|
WO2012154935A1
(en)
|
2011-05-12 |
2012-11-15 |
Eisai R&D Management Co., Ltd. |
Biomarkers that are predictive of responsiveness or non-responsiveness to treatment with lenvatinib or a pharmaceutically acceptable salt thereof
|
|
ES2622401T3
(es)
|
2011-05-17 |
2017-07-06 |
Eisai R&D Management Co., Ltd. |
Método de predicción de la eficacia de un inhibidor de la angiogénesis
|
|
JP6038128B2
(ja)
|
2011-06-03 |
2016-12-07 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
|
|
MX368257B
(es)
|
2011-08-01 |
2019-09-26 |
Genentech Inc |
Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer.
|
|
WO2013043569A1
(en)
*
|
2011-09-20 |
2013-03-28 |
Vical Incorporated |
Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
HK1203971A1
(en)
*
|
2012-05-15 |
2015-11-06 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
|
|
JP2015517511A
(ja)
|
2012-05-16 |
2015-06-22 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｃｄ３７抗体とｉｃｅ（イフォスファミド、カルボプラチン、エトポシド）の併用
|
|
PL2904011T3
(pl)
*
|
2012-10-02 |
2018-01-31 |
Bristol Myers Squibb Co |
Połączenie przeciwciał anty-kir i przeciwciał anty-pd-1 w leczeniu raka
|
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
|
KR20150098605A
(ko)
*
|
2012-12-21 |
2015-08-28 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
퀴놀린 유도체의 비정질 형태 및 그의 제조방법
|
|
CA3150658A1
(en)
|
2013-01-18 |
2014-07-24 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
|
JP5654715B1
(ja)
|
2013-02-28 |
2015-01-14 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
テトラヒドロイミダゾ［１，５−ｄ］［１，４］オキサゼピン誘導体（ＴＥＴＲＡＨＹＤＲＯＩＭＩＤＡＺＯ［１，５−ｄ］［１，４］ＯＸＡＺＥＰＩＮＥＤＥＲＩＶＡＴＩＶＥ）
|
|
BR112015023120A2
(pt)
|
2013-03-15 |
2017-11-21 |
Genentech Inc |
método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado
|
|
NZ714049A
(en)
*
|
2013-05-14 |
2020-05-29 |
Eisai R&D Man Co Ltd |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
|
BR112015029386B1
(pt)
|
2013-06-26 |
2023-11-14 |
Eisai R&D Management Co., Ltd. |
Uso de eribulina e lenvatinibe como terapia de combinação e kit
|
|
US9948862B2
(en)
|
2013-11-12 |
2018-04-17 |
Casio Computer Co., Ltd. |
Data display apparatus which controls display of a plurality of data, image display apparatus which individually displays a series of images, data display method, image display method, and storage medium
|
|
JP6287148B2
(ja)
|
2013-12-10 |
2018-03-07 |
いすゞ自動車株式会社 |
エンジンの過給システム
|
|
US9174998B2
(en)
|
2013-12-25 |
2015-11-03 |
Eisai R&D Management Co., Ltd. |
(6S,9aS)-N-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound
|
|
PE20170255A1
(es)
*
|
2014-01-24 |
2017-03-22 |
Dana Farber Cancer Inst Inc |
Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
|
|
SG11201606428UA
(en)
*
|
2014-02-04 |
2016-09-29 |
Incyte Corp |
Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
|
|
PT3524595T
(pt)
|
2014-08-28 |
2022-09-19 |
Eisai R&D Man Co Ltd |
Derivado de quinolina altamente puro e método para produção do mesmo
|
|
KR102662228B1
(ko)
|
2015-03-04 |
2024-05-02 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
|
WO2016196389A1
(en)
|
2015-05-29 |
2016-12-08 |
Bristol-Myers Squibb Company |
Treatment of renal cell carcinoma
|
|
MX373231B
(es)
|
2015-06-16 |
2020-05-08 |
Eisai R&D Man Co Ltd |
Agente anticancerigeno.
|
|
CA2986999C
(en)
|
2015-06-23 |
2023-08-08 |
Eisai R&D Management Co., Ltd. |
Crystal of (6s,9as)-n-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2h-pyrazino[2,1-c][1,2,4]triazine-1(6h)-carboxamide
|
|
CN107305202B
(zh)
|
2016-04-22 |
2020-04-17 |
北京睿创康泰医药研究院有限公司 |
分析甲磺酸乐伐替尼及其制剂杂质的hplc方法及杂质作参比标准的用途
|
|
US12303505B2
(en)
|
2017-02-08 |
2025-05-20 |
Eisai R&D Management Co., Ltd. |
Tumor-treating pharmaceutical composition
|
|
PL3384901T3
(pl)
|
2017-04-04 |
2025-01-13 |
Synthon B.V. |
Kompozycja farmaceutyczna zawierająca mesylan lenwatynibu
|
|
US10583133B2
(en)
|
2018-03-12 |
2020-03-10 |
Shilpa Medicare Limited |
Pharmaceutical compositions of lenvatinib
|
|
EP4147689A1
(en)
|
2021-09-13 |
2023-03-15 |
Lotus Pharmaceutical Co., Ltd. |
Lenvatinib formulation
|